Evaluating Intravenous Calcium Gluconate to Reduce Blood Loss After Vaginal Delivery

What this Trial Is About

Postpartum hemorrhage is a leading cause of health problems for mothers after childbirth, with some women experiencing significant drops in hemoglobin levels even without obvious bleeding. This can lead to anemia, fatigue, delayed recovery, and more medical care. Calcium plays a key role in uterine muscle contraction and blood clotting, and this study aims to evaluate if giving intravenous calcium gluconate right after umbilical cord clamping can reduce blood loss following vaginal delivery. In this randomized, double-blind trial, participants will be assigned to receive either intravenous calcium gluconate diluted in saline or a saline placebo immediately after umbilical cord clamping during vaginal delivery. The study drugs are given during the third stage of labor. Neither participants nor healthcare providers will know which treatment is given. The study compares blood loss effects between these two groups. Participants will have blood tests during their hospital stay to measure changes in hemoglobin levels and other outcomes related to postpartum bleeding. Researchers will track the proportion of women with a hemoglobin drop of 2 gdL or more and the average hemoglobin change. Secondary outcomes include diagnosed postpartum hemorrhage, need for extra medications, blood transfusions, iron treatments, hospital stay length, and overall maternal health. The study will continue until hospital discharge, with follow-up up to 30 days for some participants.

Administration Of Calcium Gluconate for The Reduction of Blood Loss During Vaginal Delivery